Jeff Yass Susquehanna International Group
Jeff Yass is a co-founder of Susquehanna International Group (SIG), a major global trading and market-making firm. SIG is known for options expertise, quantitative trading, and a training culture grounded in probabilistic decision-making. Yass’s firm is influential across derivatives markets even though it is less of a traditional long-only stock-picking franchise.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.26B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$2.12B |
| 3 |
Apple
AAPL
|
+$986M |
| 4 |
Amazon
AMZN
|
+$676M |
| 5 |
Kenvue
KVUE
|
+$501M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.26B |
| 2 |
iShares MSCI EAFE ETF
EFA
|
+$638M |
| 3 |
Microsoft
MSFT
|
+$630M |
| 4 |
Meta Platforms (Facebook)
META
|
+$578M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$453M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 90.81% |
| 2 | Technology | 2.36% |
| 3 | Consumer Discretionary | 1.65% |
| 4 | Financials | 1.08% |
| 5 | Healthcare | 0.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EMX
11126
DELISTED
EMX Royalty
EMX
| $64.4K | ﹤0.01% |
+36,193
| New | +$66.3K |
|
11127
CALL
Oric Pharmaceuticals
ORIC
$1.42B
| $64.1K | ﹤0.01% |
10,600
-21,600
| -67% | -$177K |
|
|
ADVM
11128
DELISTED
Adverum Biotechnologies
ADVM
| $64.1K | ﹤0.01% |
4,270
+1,916
| +81% | +$34.4K |
|
|
HERZ
11129
Herzfeld Credit Income Fund
HERZ
$32M
| $64K | ﹤0.01% |
2,251
+946
| +72% | +$30.5K |
|
|
TRVG
11130
trivago
TRVG
$397M
| $63.9K | ﹤0.01% |
12,164
-23,867
| -66% | -$144K |
|
|
BTCY
11131
DELISTED
Biotricity, Inc. Common Stock
BTCY
| $63.8K | ﹤0.01% |
+30,533
| New | +$73.8K |
|
|
HYZN
11132
CALL
DELISTED
Hyzon Motors Inc. Class A Common Stock
HYZN
| $63.6K | ﹤0.01% |
1,018
-92
| -8% | -$6.22K |
|
11133
CALL
Beyond Air
XAIR
$5.61M
| $63.5K | ﹤0.01% |
69
| – | – |
|
11134
NN Inc
NNBR
$295M
| $63.4K | ﹤0.01% |
34,080
+23,504
| +222% | +$55.2K |
|
11135
Natural Health Trends
NHTC
$14.7M
| $63K | ﹤0.01% |
+11,769
| New | +$64K |
|
11136
CALL
Celularity
CELU
$60.8M
| $62.9K | ﹤0.01% |
28,590
| – | – |
|
11137
Precipio
PRPO
$52.4M
| $62.6K | ﹤0.01% |
+11,156
| New | +$75.3K |
|
11138
PUT
GoPro
GPRO
$112M
| $62.5K | ﹤0.01% |
19,900
-600
| -3% | -$2.28K |
|
|
IMMP
11139
CALL
Immutep
IMMP
$56.1M
| $62.3K | ﹤0.01% |
32,800
-68,700
| -68% | -$139K |
|
|
PSTX
11140
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $62.1K | ﹤0.01% |
26,090
-15,280
| -37% | -$32K |
|
|
ICD
11141
PUT
DELISTED
Independence Contract Drilling, Inc.
ICD
| $61.5K | ﹤0.01% |
20,500
-800
| -4% | -$2.35K |
|
11142
PUT
Accuray
ARAY
$31.3M
| $61.5K | ﹤0.01% |
+22,600
| New | +$74.5K |
|
|
VISL
11143
DELISTED
Vislink Technologies, Inc. Common Stock
VISL
| $61.3K | ﹤0.01% |
16,687
-2,003
| -11% | -$9.91K |
|
11144
Cosmos Holdings
COSM
$21.8M
| $61.3K | ﹤0.01% |
39,031
+7,424
| +23% | +$12.8K |
|
11145
PUT
Caesarstone
CSTE
$111M
| $61.2K | ﹤0.01% |
14,300
-36,500
| -72% | -$176K |
|
|
11146
Oric Pharmaceuticals
ORIC
$1.42B
| $61K | ﹤0.01% |
10,089
-887
| -8% | -$7.27K |
|
|
TTOO
11147
PUT
DELISTED
T2 Biosystems, Inc
TTOO
| $60.5K | ﹤0.01% |
+2,752
| New | +$71.8K |
|
11148
PUT
ICL Group
ICL
$7.32B
| $60.5K | ﹤0.01% |
10,900
-6,700
| -38% | -$40.4K |
|
11149
Deswell Industries
DSWL
$47.8M
| $60.5K | ﹤0.01% |
25,733
-6,722
| -21% | -$16.9K |
|
11150
MaxCyte
MXCT
$132M
| $60.1K | ﹤0.01% |
19,270
-23,745
| -55% | -$95.5K |
|
Similar funds
Jeff Yass's Q3 2023 Portfolio in Review
As of Q3 2023, Jeff Yass held 13,532 positions worth $481B, down 2.3% from $492B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Jeff Yass's Q3 2023 filing shows 1,585 new, 5,250 increased, 4,926 reduced and 1,614 closed positions. Its largest new stake was iShares JPMorgan USD Emerging Markets Bond ETF: 632,356 shares worth $52.2M. The largest sale was NVIDIA, an estimated $1.26B.
By sector, the portfolio is most concentrated in Miscellaneous at 91% of assets, up from 90% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jeff Yass's largest Q3 2023 buy was iShares JPMorgan USD Emerging Markets Bond ETF: 632,356 shares worth $52.2M.
- Jeff Yass added most to State Street SPDR S&P 500 ETF Trust in Q3 2023, an estimated $3.26B increase.
- Jeff Yass's biggest Q3 2023 reduction was NVIDIA, cutting an estimated $1.26B.
- Jeff Yass fully exited Magellan Midstream Partners, L.P. in Q3 2023, selling an estimated $45.6M.
- Jeff Yass's ten largest holdings make up 28% of its $481B portfolio in Q3 2023.
- Jeff Yass opened 1,585 new positions and closed 1,614 in Q3 2023.
- Jeff Yass's portfolio value fell 2.3% quarter-over-quarter to $481B.
Based on Susquehanna International Group's 13F filing for Q3 2023, filed 14 Nov 2023.